Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics, Inc. (INDP) entered into a Stock Purchase Agreement on September 8, 2026 to conduct a private placement of 20,338,974 shares of common stock for aggregate gross proceeds of approximately $24.0 million, before expenses. The purchase price per share equals the “Nasdaq Minimum Price,” as defined in the agreement, plus $0.015 per share.
The company currently intends to use the net proceeds for working capital, research and development and other general corporate purposes, including potential early-stage research and preclinical evaluation of a neurotechnology and neural-network-based device for certain sleep-related conditions. Closing is subject to customary conditions and is expected to occur within up to fifteen business days after September 8, 2026, and the company has agreed to seek registration of the resale of the shares after closing.
Indaptus Therapeutics, Inc. (INDP) amended its at-the-market equity program by entering into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co. on August 28, 2026. The program permits Indaptus to sell shares of common stock with an aggregate maximum gross sales price of $100,000,000 through or to H.C. Wainwright as sales agent or principal, subject to share-authorization and Form S-3 eligibility limits; this $100,000,000 cap applies only to shares sold after the new agreement’s execution date.
Sales will be made under an ATM prospectus supplement and base prospectus forming part of Indaptus’s shelf registration statement on Form S-3, and Indaptus will pay H.C. Wainwright a 3.0% placement fee on shares sold when it acts as sales agent. Indaptus retains discretion over whether to sell shares, may set daily share and price parameters, and may suspend the program at any time.
Indaptus Therapeutics, Inc. (INDP) announced that on September 2, 2026, director Tim Ruan notified the company’s Board of Directors of his resignation, effective immediately. The company states that his resignation was not due to any disagreement regarding operations, policies, or practices.
The report is signed on behalf of Indaptus Therapeutics, Inc. by Chief Executive Officer Junyi Dai. Indaptus’s common stock, with a par value of $0.01 per share, is listed on the Nasdaq Capital Market under the symbol INDP.
Indaptus Therapeutics, Inc. (INDP) filed an amendment to its at-the-market offering prospectus covering the potential sale of up to $100,000,000 of common stock under an Amended and Restated At-The-Market Offering Agreement with H.C. Wainwright & Co. The amendment’s sole purpose is to fully replace and correct the prior dilution section, fixing clerical errors in the June 30, 2026 net tangible book value calculations and related dilution figures. As of this amendment, no shares have been sold under the program. Based on an assumed sale at $1.14 per share, pro forma net tangible book value would rise from $0.09 to $0.49 per share, implying illustrative dilution of $0.65 per share to new investors.
Indaptus Therapeutics, Inc. (INDP) entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC on August 28, 2026. The agreement allows Indaptus to issue and sell shares of its common stock from time to time through or to Wainwright under an at-the-market equity program.
The program covers up to $100,000,000 in aggregate gross sales price of common stock, in addition to any shares previously sold under the prior 2022 agreement. Sales are made under the company’s effective Form S-3 shelf registration statement and an August 31, 2026 ATM prospectus supplement. Wainwright acts as sales agent and may also act as principal under separate terms agreements, earning a 3.0% fee on gross sales when acting as agent. Neither party is obligated to sell or purchase shares, and the offering can be suspended at any time.
Indaptus Therapeutics, Inc. (INDP) has established an amended at-the-market equity program to sell up to $100,000,000 of common stock from time to time through or to H.C. Wainwright & Co. under an August 28, 2026 offering agreement, replacing a 2022 ATM. Wainwright will act as sales agent and/or principal and receive a 3.0% commission on gross proceeds. At August 26, 2026, common shares outstanding were 133,242,324, and an illustrative sale of 87,719,298 shares at $1.14 would raise the full capacity.
Net tangible book value at June 30, 2026 was $13.3 million ($0.10 per share); assuming full ATM usage at $1.14, pro forma net tangible book value would be $110.3 million or $0.50 per share, implying dilution of $0.64 to new investors. The company highlights significant risks, including a going-concern explanatory paragraph from its auditor and the absence of any active clinical development programs pending additional financing and strategic review of its Decoy20 immunotherapy platform.
Indaptus Therapeutics, Inc. (INDP) filed a prospectus to register the resale of up to 58,895,000 shares of common stock held by existing investors. The company is not selling any shares and will receive no proceeds; all sale proceeds go to the selling stockholders.
The registered shares comprise 20,000,000 shares issued in a June 2026 private placement and 38,895,000 shares issued upon conversion of Series AAA preferred stock tied to a December 2025 investment and a March 2026 share transfer that resulted in a change of control. These shares equal about 44.2% of the 133,242,324 shares outstanding.
Indaptus is a clinical-stage biotechnology company centered on its Decoy20 immunotherapy platform, but it has no active clinical development programs and has discontinued enrollment in all Decoy20 studies while it evaluates strategic alternatives. Its auditor’s report referenced substantial doubt about the company’s ability to continue as a going concern, and recent ownership and board changes have concentrated control among new stockholders.
Indaptus Therapeutics, Inc. is registering for resale up to 58,895,000 shares of Common Stock, all to be sold by existing holders. The company is not selling shares in this transaction and will receive no proceeds from these resales.
The registered shares comprise 20,000,000 shares sold in a June 17, 2026 private placement for $12.0 million and 38,895,000 shares issued upon conversion of 259,300 Series AAA Preferred originally sold to David Lazar and later transferred under a March 2026 secondary sale agreement. As of this prospectus, these 58,895,000 shares equal 44.2% of the 133,242,324 shares outstanding, creating a sizable potential resale overhang.
Indaptus, a clinical-stage immunotherapy company, has halted enrollment in all Decoy20 trials, has no active clinical programs, and is evaluating strategic alternatives, including transactions or new research initiatives. Recent financing history includes multiple 2024–2026 equity rounds, a now-terminated $20.0 million equity line, a 1-for-28 reverse stock split, and a December 2025 preferred investment that led to a March 2026 change of control. The most recent audit report includes a going-concern explanatory paragraph.
Indaptus Therapeutics, Inc. is a clinical-stage biotech that has halted further clinical development of its Decoy20 program and is actively evaluating strategic alternatives, including a potential investment in or acquisition of an operating business. During the quarter it also initiated a neurological and sleep research collaboration in China and engaged new scientific consulting focused on data-driven health and neurophysiological signals.
For the three months ended June 30, 2026, net loss narrowed to $1.8 million from $5.2 million a year earlier, driven by an 83% reduction in research and development expenses and a 37% decline in general and administrative costs as clinical activities and headcount were scaled back. For the six-month period, net loss fell to $4.3 million from $9.8 million.
Liquidity improved through a December 2025 preferred stock investment that converted into 111,000,000 common shares and a June 17, 2026 private placement of 20,000,000 common shares at $0.60 per share, generating approximately $12.0 million in gross proceeds. As of June 30, 2026, cash and cash equivalents were $7.6 million and certificates of deposit totaled $4.0 million. Management believes these resources fund operations through the second quarter of 2027, yet discloses substantial doubt about the company’s ability to continue as a going concern given ongoing losses, strategic uncertainty, and future financing needs.